Articles | Volume 11, issue 4
https://doi.org/10.5194/jbji-11-395-2026
© Author(s) 2026. This work is distributed under the Creative Commons Attribution 4.0 License.
Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting
Cited articles
Abduljalil, H., Bartie, K., Bal, A., Rautemaa-Richardson, R., Williams, C., Kean, R., and Ramage, G.: Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro, J. Antimicrob. Chemoth., 81, dkag058, https://doi.org/10.1093/jac/dkag058, 2026.
Burnett, Y. J., Spec, A., Ahmed, M. M., Powderly, W. G., and Hamad, Y.: Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy, Antimicrob. Agents Ch., 65, e01876-20, https://doi.org/10.1128/AAC.01876-20, 2021.
CDC (Centre for Disease Control): Data and Statistics on Candidemia, https://www.cdc.gov/candidiasis/data-research/facts-stats/index.html, last access: April 2024.
Chiurlo, M.: P3398 First case of Candida glabrata prosthetic knee infection treated with rezafungin: case report, ECCMID, Copenhagen, https://elibrary.escmid.org/? search[from]=0&search[query]=chiurlo&search[date]=&tab=docs#results (last access: 1 July 2026), April 2023.
Cidara Therapeutics: Rezzayo (rezafungin) patient information leaflet (via Medicines.org), https://www.medicines.org.uk/emc/files/pil.15479.pdf, last access: February 2025.